Test Price
2,800 AED✅ Home Collection Available
LMNA Gene Lipodystrophy Type 2, Familial Partial Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary: Clinically validated next-generation sequencing (NGS) test for familial partial lipodystrophy type 2 (FPLD2), detecting pathogenic LMNA variants with 99.9% diagnostic sensitivity. Premium home collection across all Emirates using ISO-certified cold-chain logistics. Includes mandatory pre-test genetic counseling and post-test telephone clinical interpretation by a DHA-licensed geneticist. WhatsApp direct billing verification for all major UAE insurers.
Key Metrics: Price 2,800 AED | Turnaround time 3–4 weeks | Sample: Peripheral whole blood | Method: NGS full gene coverage at 100x depth
Test Overview & Methodology
This test uses Next-Generation Sequencing to analyze the entire coding region of the LMNA gene for mutations causing familial partial lipodystrophy type 2 (Dunnigan-type), a rare metabolic disorder characterized by insulin resistance, hypertriglyceridemia, and regional fat loss. It is ordered by endocrinologists, geneticists, and general physicians in the UAE to confirm diagnosis, guide lifestyle and leptin replacement therapy, and assess cardiovascular risk.
| Feature | Our LMNA NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next-Generation Sequencing (full gene coverage, 100x depth) | Sanger sequencing (single exon or known mutation only) |
| Diagnostic Yield | >99% for known pathogenic variants; detects novel mutations | Limited to pre‑specified variant; misses rare/large deletions |
| Turnaround Time | 3 – 4 weeks | 4 – 6 weeks (if multiple exons tested) |
| Result Interpretation | Comprehensive report with ACMG classification & clinical correlation | Variant-specific report; limited clinical annotation |
Physician Insight & Safety Protocols
“A positive LMNA mutation confirms the clinical diagnosis of familial partial lipodystrophy type 2, but must be interpreted alongside metabolic parameters and family history. This genetic result is a powerful tool for personalized risk stratification. I remind patients that medication adjustments should only be made under medical supervision.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Safety
Clinical Safety Notice
Do not discontinue any prescribed medication (e.g., insulin, fibrates, metformin) without consulting your doctor. Sudden cessation may precipitate severe metabolic decompensation, including hypertriglyceridemia or pancreatitis. Always maintain prescribed diet and exercise routines.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with acute febrile illness, hemodynamic instability, or blood transfusion within 14 days (may interfere with DNA extraction).
- Exclusion: Inability to provide informed consent or mandatory genetic counseling session (required per UAE PDPL and Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Emergency Red Flag: After receiving results, if you experience sudden severe hypertriglyceridemia (>10 mmol/L), acute pancreatitis symptoms (severe epigastric pain, vomiting), or new‑onset chest pain, immediately visit the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What is the purpose of the LMNA gene lipodystrophy test?
Snippet Answer: This genetic test identifies pathogenic variants in the LMNA gene that cause familial partial lipodystrophy type 2, guiding personalized management of metabolic and cardiovascular risks.
The test is used to confirm a clinical suspicion of FPLD2, differentiate it from other forms of lipodystrophy, and inform treatment decisions such as metreleptin therapy. It is also valuable for family cascade screening once a mutation is known.
2. How is the test performed and what sample is needed?
Snippet Answer: A simple blood sample (2–5 mL in EDTA tube) or a single drop on an FTA card is collected during a home visit by a DHA-licensed phlebotomist; DNA is then extracted and sequenced.
Our VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection service operates daily from 8 AM to 11 PM across the UAE. No fasting is required. The sample is transported in an ISO‑certified cold chain to our central laboratory in Dubai Healthcare City.
3. How long does it take to receive results, and how are they interpreted?
Snippet Answer: Results are available in 3 to 4 weeks and include a detailed report interpreted by a clinical geneticist, with telephonic post‑counseling to explain findings and clinical implications.
The report classifies variants according to ACMG guidelines and provides clinical recommendations. A genetic counselor will call within 48 hours of report release to discuss results, answer questions, and coordinate follow‑up care.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE complies with all UAE federal laws governing health data and genetic information. Our processes are aligned with:
- Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data (PDPL) – ensuring the confidentiality and security of your genetic and health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the digital management and storage of electronic health records.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing the legal framework for clinical consent, practice standards, and patient safety.
All sample handling, sequencing, and reporting are performed at our DHA-licensed facility in Dubai Healthcare City under strict quality management systems.
Clinical & Logistical Metadata
| Test Name | LMNA Gene Lipodystrophy Type 2, Familial Partial Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube or FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS), full coding region of LMNA, 100x coverage |
| ICD-10-CM Code | E88.1 (Lipodystrophy, not elsewhere classified) |
| LOINC Code | 55233-1 (Genetic analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians